In addition, comparative analysis of the median expression levels of BRIP1 between different patient subgroups identified based on hormone receptor status (i.e. estrogen receptor ER, progesterone receptor PR, human epidermal growth factor receptor 2 HER-2), molecular subtypes (i.e. basal-like, luminal A, luminal B, Her+) or histological characteristics (i.e. tumor stages) showed that its expression was positively correlated with an unfavorable outcome (see Fig. 2b–d). Here, BRIP1 is linked to neoplasm.